About Quell Therapeutics

Quell Therapeutics engineers regulatory T cells to restore immune balance in people with severe autoimmune conditions and transplant recipients. The company's proprietary platform creates stable, targeted Treg therapies designed to deliver durable disease control, potentially with a single dose. By harnessing natural immune regulation, Quell addresses the root cause rather than suppressing symptoms. The technology combines phenotype-locked Tregs with disease-specific targeting. Quell's pipeline includes therapies for type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis, and liver transplant rejection. The company collaborates with leading institutions and pharmaceutical partners including AstraZeneca to accelerate development.